Jul. 23 at 12:37 PM
I did research on
$HLN, a biotech stock currently in oversold territory. It is a sister company of GSK, demerged from GSK in 2022. I see it as a long-term hold with potential gains. It has several buy ratings and runs a profitable pharma business. Obviously, it is backed by GSK.
The only downside risk is litigation related to the Zantac drug, which is still in court. HLN was one of many manufacturers of the OTC version for gas relief, but they clarified in a press release that they have no involvement. Other than that, there is no publicly available negative news.
